Literature DB >> 31666345

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.).

Jonathan Weiss1, Martin Peifer2,3, Carmen D Herling4, Lukas P Frenzel4, Michael Hallek4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31666345      PMCID： PMC6821598          DOI： 10.3324/haematol.2019.232835

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

1.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors:  Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Cancer Discov       Date:  2018-12-04       Impact factor: 39.397

2.  Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.

Authors:  Eugen Tausch; William Close; Anna Dolnik; Johannes Bloehdorn; Brenda Chyla; Lars Bullinger; Hartmut Döhner; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

3.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Authors:  Carmen D Herling; Nima Abedpour; Jonathan Weiss; Anna Schmitt; Ron Daniel Jachimowicz; Olaf Merkel; Maria Cartolano; Sebastian Oberbeck; Petra Mayer; Valeska Berg; Daniel Thomalla; Nadine Kutsch; Marius Stiefelhagen; Paula Cramer; Clemens-Martin Wendtner; Thorsten Persigehl; Andreas Saleh; Janine Altmüller; Peter Nürnberg; Christian Pallasch; Viktor Achter; Ulrich Lang; Barbara Eichhorst; Roberta Castiglione; Stephan C Schäfer; Reinhard Büttner; Karl-Anton Kreuzer; Hans Christian Reinhardt; Michael Hallek; Lukas P Frenzel; Martin Peifer
Journal:  Nat Commun       Date:  2018-02-20       Impact factor: 14.919
  3 in total
  4 in total

1.  Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Authors:  Piers Blombery; Ella R Thompson; Tamia Nguyen; Richard W Birkinshaw; Jia-Nan Gong; Xiangting Chen; Michelle McBean; Rachel Thijssen; Thomas Conway; Mary Ann Anderson; John F Seymour; David A Westerman; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Blood       Date:  2020-03-05       Impact factor: 22.113

Review 2.  Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer.

Authors:  Erinna F Lee; W Douglas Fairlie
Journal:  Biochem Soc Trans       Date:  2021-11-01       Impact factor: 5.407

3.  Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer.

Authors:  Li Wang; Lei Yu; Jian Shi; Feng Li; Caiyu Zhang; Haotian Xu; Xiangzhe Yin; Lixia Wang; Shihua Lin; Anastasiia Litvinova; Yanyan Ping; Shangwei Ning; Hongying Zhao
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

Review 4.  BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.

Authors:  Magdalena Klanova; Pavel Klener
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.